~~<i id='4655E2311D'><strike id='4655E2311D'><tt id='4655E2311D'><pre id='4655E2311D'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：fashion 2025-09-28 02:44:11 Page View：834

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Parkinson’s finding may lead to tests and, someday, treatments
Next article： Peter Hotez and the public health issue of online harassment

leisure time

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Mystery swirls around US soldier who entered North Korea days ago, officials say

2:55AgroupoftouristsstandnearaborderstationatPanmunjomintheDemilitarizedZoneinPaju,SouthKorea,July18

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Are infertility treatments 'essential' during the Covid

Aninfertilityspecialistspointstoahumaneggcellafterinsemination.IVANCOURONNE/AFPviaGettyImagesAstheCo